Theranostics
Imaging / Therapy
Cell Theranostics, Inc.
Cell Theranostics is a late-stage Phase 3 biotech company specializing in the field of theranostic nuclear medicine through chelation technologies focused in cancer, cardiovascular, neuroendocrine, diabetes and ischemia-based diseases.
The company acquired five platform technologies that are in late-stage development from The University of Texas M.D. Anderson Cancer Center.
Theranostics
Theranostic medicine is a major step forward in making personalized medicine a reality. It is the combination of target specific diagnostic imaging and compatible target specific therapy at the molecular level.
Cancer Imaging
Before the development of FDG-PET/CT, medical oncologists were limited to standard X-ray, CT, MRI, Ultrasound and some utilization of nuclear imaging. FDG-PET/CT ushered in a new approach to cancer diagnostics by creating 3-D images at the molecular level. Oncardia has the potential to shift the paradigm to a more accurate, accessible, and cost-effective way to diagnose and stage cancer without the drawbacks of FDG used in PET-CT imaging.
Cardiac Imaging
Nuclear cardiology needs an agent that eliminates the drawbacks associated with perfusion imaging to diagnose the presence and extent of myocardial ischemia. At Cell Theranostics we are making that a reality.
Contact Us
Want to learn more about Cell Theranostics or have a question about our approach? Use the contact form and let’s start a conversation.